English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

issue of the journal, Hulgan et al. [1] shed light on the potential role that genetic polymorphisms may play in predisposing HIV-infected patients receiving HAART to lipoatrophy. Since lipodystrophy was first described in 1998 [2], a number of studies have been published implicating antiretroviral therapy as its sole cause [3-6]. Initially, both fat atrophy and fat hyperplasia were thought to be manifestations of a single syndrome because they shared some common features. Subsequently, researchers found that although some antiretroviral agents were associated with eac clinical syndrome, drugs in all classes were associated o some degree with lipoatrophy, and some protease inhibitors were associated with lipohypertrophy, suggesting that these clinical manifestations might be different, but related, syndromes.

Human Immunodeficiency Virus–Associated Lipoatrophy: Letting the Genome Out of the Bottle